Locoregional IL-2 low dose applications for gastrointestinal tumors

Table 1 Patients’ characteristics. A. Once weekly local IL-2 application. B. Once monthly local IL-2 application

No.	Sex	Primary tumor	Metastases	Neoplastic ascites	Route and dose of IL-2 application	Necrosis induction
W1	M	Pancreatic Ca	Liver, abdominal lymph nodes	-	1.5 MIU i.p.	-
W2	F	Stomach Ca	Liver, abdominal lymph nodes	-	4.5 MIU i.p.	-
W3	F	Colorectal Ca	Liver, lung	-	4.5 MIU i.p.+i.t.	Yes
W4	F	Colorectal Ca	Liver, abdominal lymph nodes	-	4.5 MIU i.t.	Yes
W5	M	Colorectal Ca	Peritoneum	+	1.5 MIU i.p.+i.t.	-
W6	F	Ovarian Ca	Lung, peritoneum, spleen	+	4.5 MIU i.t.	-
W7	F	Mammary Ca	Liver, lung, peritoneum	+	4.5 MIU i.p.	-
W8	M	Hemangiosarcoma	Liver, peritoneum, abdominal lymph nodes	+pleural effusion	4.5 MIU i.p.+i.t.	-
No.	Sex	Primary tumor	Metastases	Neoplastic ascites	Route of IL-2 application	Necrosis induction
M1	M	HCC, liver cirrhosis		-	4.5/9 MIU i.t.	-
M2	M	HCC, liver cirrhosis		-	4.5 MIU i.t.	Yes
M3	M	Abdominal mesothelioma	Peritoneum	-	9 MIU i.t.+i.p.	-
M4	F	Colorectal Ca	Liver	-	9 MIU i.t.	Yes
M5	F	Mammary Ca	Liver, bone, skin	–	1.5 MIU i.t.	-
M6	F	Mammary Ca	Liver	-	4.5/9 MIU i.t.	-
M7	M	HCC, liver cirrhosis		-	4.5 MIU i.t.	Yes

Ca, carcinoma; HCC, hepatocellular carcinoma; i.p., intraperitoneal; i.t., intratumoral; W, weekly IL-2 application; M, monthly IL-2 application.

Table 2 Therapeutic effect after 3^rd mo and survival. A. Once weekly local IL-2 application. B. Once monthly local IL-2 application

No.	Sex	Primary tumor	Clinical effect	Neoplastic effusion	Karnofsky before and after treatment (%)	*Survival mo
W1	M	Pancreatic Ca	PD	-	30-30	4
W2	F	Stomach Ca	PD	-	80-60	3
W3	F	Colorectal Ca	PD	-	80-60	L
W4	F	Colorectal Ca	SD	-	50-80	28
W5	M	Colorectal Ca	PD	Complete reduction	70-90	10
W6	F	Ovarian Ca	PD	Failure	60-50	2
W7	F	Mammary Ca	PD	Failure	60-40	1
W8	M	Hemangiosarcoma	PD	Complete reduction	50-80	12
No.	Sex	Primary tumor	Clinical effect	Karnofsky before and after treatment (%)	*Survival mo
M1	M	HCC Liver cirrhosis	PD	70-70	4
M2	M	HCC Liver cirrhosis	SD	80-80	24A
M3	M	Abdominal mesothelioma	PD	80-50	6
M4	F	Colorectal Ca	PD	80-70	L
M5	F	Mammary Ca	PD	40-40	1
M6	F	Mammary Ca	PD	80-80	L
M7	M	HCC Liver cirrhosis	SD	90-90	27
M8	F	HCC Liver cirrhosis	SD	80-90	24A

I survival since the start of IL-2 therapy till death; W, weekly IL-2 application; M, monthly IL-2 application; A, alive; L, lost for follow-up; Ca, carcinoma; HCC, hepatocellular carcinoma; PD, progressive disease; SD, stable disease.